The a16z Show · Wednesday, September 2, 2026
Moderna CEO Stéphane Bancel indicated that the company is working with regulators to make the personalized mRNA melanoma treatment available to patients as soon as possible, ideally in 2027. He also mentioned the logistical challenge of manufacturing thousands of different medicines, one patient at a time.
“We will share data very soon at a big oncology conference, which is what the field does.”
“We are working very out already with regulators to file so that the drug can be available to patient as soon as possible and we hope in 2027 and then we're going to try to make it as fast as we can.”
“The factory is ready in Massachusetts, but we have figured out how to make and scale a product for every human being at the time.”